-
Endpoints News2 weeks ago
Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate
With its blockbuster drug Xolair set to face biosimilar competition, Novartis said it will pay up to $2 billion in upfront and certain milestone payments to...
-
Uncategorized2 weeks ago
Eisai, Alzheon Drill Down on Promising Results in High-Risk Alzheimer’s Subset
At the AD/PD annual meeting, Eisai presented real-world data suggesting Leqembi’s long-term safety and efficacy in people homozygous for APOE4, who were identified in trials as...
-
Uncategorized2 weeks agoFirst patient dosed in trial of Geographic Atrophy treatment
The first patient has been dosed in a first-in-human clinical trial of a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). CTx001, developed...
-
Endpoints News2 weeks ago
Recursion appoints former Exelixis CMO; More executive moves at Incyte
→ Recursion has hired a new top doctor, bringing on Vicki Goodman as chief medical officer. Goodman previously served as CMO of the cancer biotechs Exelixis...
-
Endpoints News2 weeks ago
AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population
AstraZeneca’s investigational antibody for chronic obstructive pulmonary disease has succeeded in two late-stage studies, despite having previously failed in a mid-stage trial. And, unexpectedly, the company...
-
GEN – Genetic Engineering & Biotechnology News2 weeks ago
Complete Genome Sequencing Reveals Malaria Mosquito Adapting to Insecticides
A sweeping population‑genomics effort has generated the first large collection of complete genomes for Anopheles darlingi, the dominant malaria vector across South America. The dataset—more than...
-
Fierce Biotech2 weeks ago
AstraZeneca’s in vivo CAR-T bet eradicates cancer in 3 of 5 patients, but death mars dataset
AstraZeneca isn’t letting a death in a China trial detract from the potential of its $1 billion in vivo bet, even as the candidate’s safety and...
-
Fierce Biotech2 weeks ago
After local tumor approval, Novocure touts positive data in metastatic pancreatic cancer
After collecting an FDA approval earlier this year for local pancreatic cancer, Novocure is putting forward positive clinical data for its electric field-based treatment in metastatic...
-
Uncategorized2 weeks agoMHRA to offer early review of non-animal data
The Medicines and Healthcare products Regulatory Agency (MHRA) will offer early review of non-animal data in a decision supporting the government’s strategy to reduce animal testing in...
-
Fierce Biotech2 weeks ago
Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditions
Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its wholly owned subsidiary, Otsuka America, in a deal that could also deliver up to...
Terns rebuffed a higher bid before selling to Merck
